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Abstract
The amyloid-β peptide (Aβ), implicated in the pathogenesis of Alzheimer's disease (AD), is
produced through sequential proteolysis of the Aβ precursor protein (APP) by β- and γ-secretases.
Thus, blocking either of these two proteases, directly or indirectly, is potentially worthwhile
toward developing AD therapeutics. β-Secretase is a membrane-tethered pepsin-like aspartyl
protease suitable for structure-based design, whereas γ-secretase is an unusual, heterotetrameric
membrane-embedded aspartyl protease. While γ-secretase inhibitors entered clinical trials first due
to their superior pharmacological properties (for example, brain penetration) over β-secretase
inhibitors, it has since become clear that γ-secretase inhibitors can cause mechanism-based
toxicities owing to interference with the proteolysis of another γ-secretase substrate, the Notch
receptor. Strategies for targeting Aβ production at the γ-secretase level without blocking Notch
signalling will be discussed. Other strategies utilizing cell-based screening have led to the
identification of novel Aβ lowering agents that likewise leave Notch proteolysis intact. The
mechanism by which these agents lower Aβ is unknown, but these compounds may ultimately
reveal new targets for AD therapeutics.
The formation of the amyloid-β peptide (Aβ) from the Aβ
precursor protein (APP) is a critical molecular event in the
pathogenesis of Alzheimer's disease (AD). For this reason,
the proteases that produce Aβ from this integral mem-
brane protein are considered key targets in the prevention
and treatment of AD [1]. β-Secretase generates the amino
terminus of Aβ, shedding the large ectodomain (β-APPs)
and leaving a 99 residue carboxy-terminal fragment (C99)
in the membrane. C99 is cleaved in the middle of its trans-
membrane domain by γ-secretase to produce Aβ. γ-Secre-
tase produces carboxy-terminal variants of Aβ, primarily a
40-residue peptide (Aβ40), but also a small proportion of
a 42 residue variant (Aβ42), as well as other minor spe-
cies. Aβ42 is much more prone to aggregation than Aβ40,
and Aβ42 is the major Aβ species found in cerebral
plaques that characterize the AD brain.
β-Secretase is a membrane-tethered enzyme in the pepsin
family of aspartyl proteases and primarily expressed in the
brain [2]. Knockout of this enzyme in mice is not lethal
and prevents Aβ production in the brain [3,4]. Neverthe-
less, concern about β-secretase as a target has been raised
by the finding that the myelin sheath of peripheral nerves
of these knockout mice are much thinner due to the
important role β-secretase plays in cleaving neuregulin-1
[5]. The extracellular catalytic domain of β-secretase has
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been successfully crystallized with bound inhibitors, ena-
bling structure-based design [6]. However, the long, shal-
low active site of β-secretase has proved challenging in
developing inhibitors with appropriate pharmacological
properties, in particular the ability to cross the blood-
brain barrier. Potent inhibitors tend to be too large and
peptide-like, although this problem is gradually being
overcome [7], and the first β-secretase inhibitors are
poised to enter clinical trials.
In contrast to β-secretase, the ubiquitously expressed γ-
secretase is a complex of four different integral membrane
proteins essential to the protease: presenilin (PS), Nicas-
trin, Aph-1, and Pen-2 [8]. These proteins assemble,
resulting in the cleavage of PS into an amino-terminal
fragment and a carboxy-terminal fragment, a necessary
step in the maturation of wild-type PS into an active com-
ponent of γ-secretase. PS contains two completely con-
served transmembrane aspartates that are essential for γ-
secretase activity and part of the compelling evidence sug-
gesting that PS is a novel, membrane-embedded aspartyl
protease. Although PS is apparently the catalytic compo-
nent of γ-secretase, it nevertheless requires the other three
components to become an active protease and maintain
activity.
Unlike the situation with β-secretase, identification of
highly potent inhibitors of γ-secretase that readily pene-
trate biological membranes has not been especially prob-
lematic. However, these compounds also interfere with
the processing of other substrates of this protease besides
APP [9], raising serious concerns about selectivity and tox-
icity. γ-Secretase can cleave a number of different single-
pass membrane proteins, including Erb-B4, E- and N-cad-
herins, CD44, the low density lipoprotein receptor, Nec-
tin-1, and the Notch receptor ligands Delta and Jagged.
However, the most pharmacologically relevant alternative
substrate is the Notch receptor itself. Signalling from this
receptor plays a role in a variety of cell differentiation
events from embryogenesis into late adulthood. The
Notch signal is initiated by interaction with a cognate lig-
and that induces shedding of the extracellular portion of
the receptor. The remaining membrane-bound stub is
then processed by PS/γ-secretase to release an intracellular
domain that translocates to the nucleus and directly inter-
acts with certain transcription factors, thereby regulating
gene expression. Because γ-secretase is essential for Notch
signaling, inhibitors of this protease can interfere with cell
differentiation. Indeed, treatment of mice with γ-secretase
inhibitors over time can cause severe gastrointestinal tox-
icity and compromise the proper maturation of B- and T-
lymphocytes [10,11]. Thus, the ability to selectively block
APP proteolysis by γ-secretase without affecting the prote-
olysis of Notch is a major goal toward realizing practical
therapeutics for AD.
Two types of compounds appear to selectively modulate
γ-secretase activity via direct interaction with the protease
or its substrate. The first of these are certain non-steroidal
anti-inflammatory drugs (NSAIDs), reported in 2001 by
the laboratories of Todd Golde and Edward Koo to be
capable of skewing the production of Aβ, lowering the
production of Aβ42, and increasing the formation of a
shorter 38 residue variant (Aβ38) [12]. These compounds
include ibuprofen, indomethacin, and sulindac sulfide.
The effects of these compounds were demonstrated in iso-
lated membranes [13], suggesting that the compounds
work directly (that is, on enzyme or substrate) instead of
through an indirect effect on a signaling or metabolic
pathway [14]. Evidence from our laboratory shows that
these compounds can also shift the site of substrate prote-
olysis catalyzed by signal peptide peptidase [15]. Because
signal peptide peptidase is a PS homolog that does not
require additional protein cofactors, the implication is
that the NSAID binding site is on PS. On the other hand,
evidence from the Golde laboratory supports the APP sub-
strate itself, specifically its juxtamembrane region, as the
direct binding site, which would explain the selectivity of
these compounds for APP versus Notch [16]. Understand-
ing how this subset of NSAIDs selectively affects APP
processing by γ-secretase is important, as one of these
compounds, R-flurbiprofen (tarenflurbil; Figure 1),
recently failed in late-stage clinical trials for the treatment
of AD due to lack of efficacy. A clearer mechanistic under-
standing may suggest structural changes to improve the
potency of this class of compounds.
Certain kinase inhibitors can also selectively affect Aβ pro-
duction at the γ-secretase level with little or no effect on
Notch proteolysis. Because ATP was found to augment the
Selective amyloid-β lowering agents that do not affect Notch  processing Figure 1
Selective amyloid-β lowering agents that do not affect Notch 
processing. Tarenflurbil and 1367 work in purified γ-secre-
tase assays, whereas LDDN-9918 was identified from a cell-
based screen and works through an unknown mechanism.BMC Neuroscience 2008, 9(Suppl 2):S4 http://www.biomedcentral.com/1471-2202/9/S2/S4
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γ-secretase cleavage of C99 to Aβ, the Greengard labora-
tory at Rockefeller University tested kinase inhibitors for
their ability to prevent Aβ production. The Abl kinase
inhibitor imatinib (Gleevec™) was found to block Aβ for-
mation without affecting Notch [17]. This action of imat-
inib was not due to an interaction with Abl kinase,
although it was assumed to be blocking some membrane-
associated kinase. Subsequently, our laboratory found
that an extract from the drug's capsules (but not imatinib
itself) could inhibit Aβ production from purified γ-secre-
tase while leaving the proteolysis of Notch unaffected
[18]. An inhibitor of Janus kinase 3 (Jak3) was also found
to show selective inhibition on purified γ-secretase (com-
pound 1367; Figure 1). Further experiments revealed a
nucleotide binding site on the γ-secretase complex. For
example, affinity-labeling with a photo-reactive azido-
substituted ATP led to its covalent attachment to the PS1
carboxy-terminal fragment. This labeling was prevented
by the imatinib extract and the Jak3 inhibitor, but not by
a transition-state analogue inhibitor (that is, directed to
the active site). These findings suggest a specific competi-
tion with ATP for binding to the γ-secretase complex at an
allosteric site.
In parallel with the above efforts, we have established a
cell-based screen to identify Aβ lowering agents that work
by novel mechanisms (as opposed to direct inhibition of
β- or γ-secretase). Specifically, we stably co-expressed APP
with a heterologous transcription factor fused to its car-
boxyl terminus along with a luciferase reporter, the
expression of which would be turned on when APP under-
went proteolytic processing and released its cytosolic
domain [19]. Screening of some 65,000 drug-like com-
pounds using this cell-based assay led to the identification
of compounds that were found to lower Aβ production in
secondary assays, and to leave Notch proteolysis unaf-
fected in tertiary assays. One of these compounds is the
symmetrical naphthylene-containing bis(carbohydra-
zone), LDDN-9918 (Figure 1). Structure-activity studies
have led to the development of a smaller, more soluble,
and more drug-like derivative (S Choi, P Maiti, T Gainer,
M Glicksman, M Wolfe, and G Cuny, unpublished
results). Elucidation of the mechanism by which this
compound lowers Aβ may lead to the identification of
new druggable targets for AD.
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